Tesamorelin not checked

Theratechnologies

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Lipodystrophy, HIV Infections, Chronic Obstructive Pulmonary Disease (COPD)
Main trialPhase 3
“Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation”In the company’s words, NCT00608023 on ClinicalTrials.gov
Other names
Egrifta

Other drugs for HIV Infections

All 36 drugs for HIV Infections

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Completed Oct 2008 TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Phase 2Terminated Dec 2011 Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Tesamorelin

Following is part of Solo: you see every change to Tesamorelin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in